Date: 2026-05-15 Price: EUR 62.65 | Forward P/E: 10.5x | P/B: 0.77x | Dividend yield: 5.67% Graham score: 4/7 (cyclical), Growth Stock Addendum applies (shr-004) Status: Stage 2 candidate, deployment pending
Arkema is a EUR 4.6B French specialty chemicals leader trading below book value (P/B 0.77x) and paying a 5.67% dividend yield. The market has priced it as if the chemicals cycle won't recover. Q1 2026 results showed the first signs of an inflection: EBITDA snapped back to EUR 283M from a trough of EUR 74M in Q4 2025. The investment thesis depends on whether that snapback is a genuine cyclical turn or a temporary geopolitical artifact (Iran/Hormuz acrylic margin spike).
Two layers of margin of safety protect against being wrong on timing: assets (book value at EUR 81/share vs current EUR 62.65) and income (5.67% dividend yield = ~17% cumulative return over 3 years even if nothing else changes). The bull case sees EUR 90-100 stock in 24 months on a confirmed cyclical recovery + battery materials growth (PVDF, PA11). The bear case sees EUR 50-55 if margins normalize and construction stays weak.
Arkema makes the boring middle of modern manufacturing — the glues holding your phone together, the resins coating your car, the polymers in your hiking boots, and the binders that hold lithium-ion battery electrodes in place. Spun off from TotalEnergies in 2006, it became Europe's biggest specialty-chemicals pure-play under a single CEO who has run it since day one.
The story is a textbook chemicals cycle that's just turning:
2022 — Peak. Post-COVID demand surge, construction booming, supply chains tight. Arkema's adjusted EPS hits EUR 10+, stock near EUR 130. Everyone's a chemicals bull.
2023-2024 — Downturn. Rates rise. Construction stops. European auto stalls. Chinese property collapses. Customers who over-ordered in 2022 now have full warehouses and don't need to buy. Destocking becomes the most-used word on earnings calls. EPS halves. Stock drops to EUR 50s.
Q4 2025 — Trough. Normalized EBITDA collapses to EUR 74M — the worst quarterly result since 2020. The market gives up on the cycle. Stock at 52-week low.
Q1 2026 — First inflection signs. EBITDA snaps back to EUR 283M (+283% sequentially, only -14% YoY). EPS beats consensus by ~10%. Management reaffirms FY26 guidance: "slight EBITDA growth at constant FX." New capacity (US PVDF, Singapore PA11) about to come online. Stock barely moves because:
This is the moment of the trade. If you wait for confirmation, you'll be paying EUR 80+ instead of EUR 63. If you buy now, you're betting the trough is genuine.
graph TD
A[Thierry Le Hénaff<br/>CEO since 2006<br/>20-yr tenure, ex-TotalEnergies] -->|Strategy & execution| B[Arkema Group]
C[TotalEnergies<br/>Former parent, fully exited 2014] -.->|Heritage| B
B --> D[Adhesive Solutions / Bostik<br/>30%+ of revenue]
B --> E[Advanced Materials<br/>PA11 Singapore, PVDF US]
B --> F[Coating Solutions<br/>UV resins, waterborne]
B --> G[Intermediates<br/>Acrylic acid, fluorochemicals]
H[Construction customers<br/>BUYERS] -->|Soft demand 2024-26| D
I[Auto OEMs<br/>BUYERS] -->|Transition ICE→EV| E
J[Battery makers<br/>CATL/Northvolt/Tesla<br/>GROWTH] -->|PVDF binders| E
K[BASF / Dow / Solvay / Wacker<br/>COMPETITORS] -.->|Pressure on margins| B
L[Berenberg / sell-side<br/>SKEPTICAL] -.->|Q1 beat is temporary| B
Key people:
Note: current CFO not verified in source material; not specified here to avoid invention.
graph LR
A[Q1 2026 EBITDA +283% sequential] --> B{Driven by?}
B -->|Bull case| C[Customer destocking ending<br/>Real demand recovery<br/>Sustainable]
B -->|Bear case| D[Iran-Hormuz disruption<br/>Acrylic spreads >$900/t<br/>Geopolitical, temporary]
C --> E[2026-28 EPS compounds<br/>Multiple expands to 14x<br/>Stock EUR 100+]
D --> F[Hormuz reopens<br/>Spreads normalize <$300/t<br/>2027 EBITDA -10%<br/>Stock EUR 50-55]
Berenberg's specific concern: Sulfur and acrylic acid spreads ballooned when Strait of Hormuz traffic was disrupted in early 2026. This boosted Arkema's Intermediates segment artificially. When Hormuz normalizes (could be months, could be quarters), those spreads collapse. Berenberg's "ChemCast" model says 2027 consensus EBITDA might be ~10% too high.
The bull rebuttal: Acrylic is only one of four segments. The recovery in Bostik (adhesives), Coatings, and Advanced Materials is genuine and based on customer activity, not geopolitics. Even strip out 100% of the acrylic windfall and Q1 still shows sequential improvement.
The auto industry is Arkema's second-biggest customer base. The transition from internal combustion to electric vehicles affects them in opposite ways:
graph LR
A[Auto industry transition] --> B[ICE vehicles declining]
A --> C[EV vehicles rising]
B -->|negative for| D[Specialty fuel additives<br/>Lubricant chemistry<br/>Catalytic chemistry<br/>NEGATIVE for Arkema]
C -->|positive for| E[PVDF battery binders<br/>Thermal management fluids<br/>Battery pack adhesives - Bostik<br/>POSITIVE for Arkema]
D --> F[Net effect?]
E --> F
F -->|Bull| G[EV chemistry value-per-vehicle<br/>~4x ICE chemistry]
F -->|Bear| H[Slower EV adoption<br/>Tesla margin compression<br/>Chinese cell makers overcapacity]
The bullish twist: A typical EV uses ~$1,500 of specialty chemicals (battery binders, thermal fluids, adhesives) vs ~$400 for a typical ICE car. If EV penetration grows, Arkema's auto exposure becomes a growth story even if total vehicle count is flat.
The bear case: Chinese cell makers (CATL, BYD) are vertically integrating and squeezing binder prices. Tesla's price cuts force the entire supply chain to take margin hits. Northvolt declared bankruptcy in late 2025 (a real Arkema customer loss).
graph TD
A[FY26 Free Cash Flow ~EUR 600M] --> B{Capital allocation choices}
B --> C[Dividend EUR 371M<br/>35% payout ratio<br/>5.67% yield maintained]
B --> D[Capex EUR 600M<br/>PVDF US, PA11 Singapore<br/>Battery materials]
B --> E[Bostik integration<br/>Acquired tech assets<br/>Restructuring costs ~EUR 100M/yr]
B --> F[Debt repayment / buybacks<br/>Minimal currently]
G[Result: zero buyback budget<br/>Growth capex bet] -.- B
The bull case: Le Hénaff is investing aggressively in the structural growth bucket (batteries, bio-based materials). Once PVDF US and PA11 Singapore are online, capex normalizes and FCF jumps. Buybacks could resume 2027+.
The bear case: EUR 600M annual capex is too much for a EUR 4.6B market cap. The company is sinking cash into capacity that may have weak end-market demand. Bostik integration is messier than disclosed.
graph LR
A[Stock at EUR 62.65] --> B[P/B 0.77x]
A --> C[Forward P/E 10.5x]
A --> D[Dividend yield 5.67%]
B --> E[Below book value<br/>Asset floor]
C --> F[Cheap on forward earnings<br/>If forward earnings are real]
D --> G[Income while waiting<br/>~17% over 3 years]
E --> H[Margin of safety]
F --> I[Inflection upside]
G --> H
H --> J[Floor: ~EUR 50<br/>Bear case]
I --> K[Ceiling: ~EUR 110-140<br/>If inflection works]
The paradox: either the forward earnings are right and the stock is dramatically cheap, or the forward earnings are wrong and the stock is fairly valued. There's no scenario where Arkema is expensive at EUR 62.65.
quadrantChart
title Arkema SWOT positioning
x-axis "Internal weakness" --> "Internal strength"
y-axis "External threat" --> "External opportunity"
quadrant-1 "STRENGTHS × OPPORTUNITIES"
quadrant-2 "WEAKNESSES × OPPORTUNITIES"
quadrant-3 "WEAKNESSES × THREATS"
quadrant-4 "STRENGTHS × THREATS"
"PVDF battery exposure": [0.85, 0.85]
"PA11 bio-polymers": [0.75, 0.80]
"20-yr CEO tenure": [0.80, 0.55]
"P/B 0.77 asset floor": [0.70, 0.45]
"5.67% dividend cushion": [0.65, 0.50]
"Bostik adhesives lead": [0.75, 0.65]
"Construction soft demand": [0.45, 0.20]
"China overcapacity": [0.40, 0.15]
"Acrylic spread fragility": [0.35, 0.25]
"Northvolt bankruptcy": [0.30, 0.20]
"EV transition (mixed)": [0.55, 0.55]
"Trade tariff exposure": [0.40, 0.20]
timeline
title Arkema FY26-28 catalyst path
section H1 2026 (already passed)
Q4 2025 trough EBITDA EUR 74M : Worst quarter
Q1 2026 EBITDA EUR 283M : First inflection signal
FY26 guidance reaffirmed : Conservative tone
section H2 2026
Q2 2026 results late Jul : Construction/auto re-test
PVDF US capacity online : EBITDA contribution begins
PA11 Singapore ramp : Specialty growth visible
section FY27
Q1 2027 results : Whether margins held
Acrylic spread normalization : Bear test
Capex normalization begins : FCF expansion
section FY28
FY27 full results : Through-cycle EPS visible
Possible buyback resumption : Capital return signal
Multiple re-rating event : Stock toward EUR 100+
Expected Value calculation:
| Scenario | Probability | 3yr Return | EV contribution |
|---|---|---|---|
| Bull | 45% | +75% | +33.75c/EUR |
| Base | 25% | +28% | +7.0c/EUR |
| Bear | 30% | 0% | 0c/EUR |
| Total EV | +40.75c/EUR |
Note: prior agent estimates put this higher at +77c/EUR using more aggressive base-case assumptions. The +40c figure here uses more conservative weights consistent with portfolio retrospective showing user stock-picking ex-SLS has lagged VWCE.
Do you believe Q1 2026 marked the trough of the chemicals cycle?
If yes → AKE.PA is a structural buy with embedded margin of safety (asset floor + dividend cushion + inflection upside).
If no → You're paying 10.5x forward earnings that may not materialize, and your protection is "only" the 5.67% dividend and 23% discount to book.
The thesis is genuinely about timing cyclical recovery, but with two layers of cushion (assets, income) that protect against being wrong on timing.
If you don't have an opinion on chemicals cycle timing, you cannot justify a concentrated bet here. VWCE captures ~0.05% AKE exposure passively + everything else diversified. That's the disciplined "pass" option.
VWCE long-term expected return: ~+8%/yr ≈ +26c/EUR over 3 years. AKE expected EV: +40-77c/EUR over 3 years (range reflects scenario uncertainty).
The math favors AKE if the inflection is real. If you're agnostic on the cycle, VWCE is the right answer.
Do you have a view on whether destocking is ending?
Tranche structure (per shr-013 cyclical entry discipline):
| Tranche | Price | Shares (of 10 budget) | Trigger |
|---|---|---|---|
| T1 | EUR 62-64 | 5-6 | Today / current price |
| T2 | EUR 56-58 | 2-3 | If retest of 2025 lows without thesis break |
| T3 | EUR 48-50 | 2-3 | Deep value retest, dividend yield 7%+ |
Exit targets (Graham IV at sustained growth):
| Target | Price | Return | Action |
|---|---|---|---|
| TP1 | EUR 75 | +20% | Trim 1/3 — Berenberg fair value zone |
| TP2 | EUR 90 | +44% | Trim 1/3 — analyst high target |
| TP3 | EUR 110+ | +75% | Trim remainder — full re-rating done |
Fundamental stops (no price stops per shr-016):
Related files:
output/graham/scores/ — no AKE.PA Stage 2 triad yet (pending deployment decision)Playbook rules invoked: